Clinical trials in a number of solid cancers including TNBC are ongoing that combine a CSF1R inhibitor with PD1-targeting drugs in the hopes that a synergistic effect might lead to an increased infiltration of ant-tumor T cells, B Cells and NK cells that can promote long-term regression of these tumors and even prevent distant recurrences. This evidence concerns the gene CSF1R and neoplasm.